206 related articles for article (PubMed ID: 31658067)
21. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
Chatterjee C; Kubo K; Pingali V
J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
[TBL] [Abstract][Full Text] [Related]
22. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
Kuek V; Phillips K; Kohler JC
Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
[TBL] [Abstract][Full Text] [Related]
23. TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana.
Cohen JC; Gyansa-Lutterodt M; Torpey K; Esmail LC; Kurokawa G
Global Health; 2005 Dec; 1():17. PubMed ID: 16336685
[TBL] [Abstract][Full Text] [Related]
24. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
25. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
Guennif S
Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
[TBL] [Abstract][Full Text] [Related]
26. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
27. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
28. Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
Bognar CLFB; Bychkovsky BL; Lopes GL
J Glob Oncol; 2016 Oct; 2(5):292-301. PubMed ID: 28717715
[TBL] [Abstract][Full Text] [Related]
29. An economic justification for open access to essential medicine patents in developing countries.
Flynn S; Hollis A; Palmedo M
J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
[TBL] [Abstract][Full Text] [Related]
30. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
31. Canada and access to medicines in developing countries: intellectual property rights first.
Lexchin J
Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
[TBL] [Abstract][Full Text] [Related]
32. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
Zapatero Miguel P
Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
[TBL] [Abstract][Full Text] [Related]
33. Academic patents and access to medicines in developing countries.
Sampat BN
Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
[TBL] [Abstract][Full Text] [Related]
34. Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K; Srivastava S
Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
[TBL] [Abstract][Full Text] [Related]
35. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
Cohen JC; Illingworth P
Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
[TBL] [Abstract][Full Text] [Related]
36. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
Lexchin J
Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
[TBL] [Abstract][Full Text] [Related]
37. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
38. Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?
Cohen-Kohler JC; Esmail LC; Cosio AP
Global Health; 2007 Dec; 3():12. PubMed ID: 18062821
[TBL] [Abstract][Full Text] [Related]
39. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
Beall RF; Attaran A
Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
